C. David Nicholson Net Worth

C. David Nicholson biography

Dr. C. David Nicholson Ph.D. serves as Lead Independent Director of the Company. Dr. Nicholson is also a member of our Compensation Committee and Corporate Governance Committee. In August 2014, Dr. Nicholson joined Actavis plc and Forest Laboratories, Inc. as Senior Vice President, Actavis Global Brands R&D. From March 2012 to August 2014, Dr. Nicholson was on the Executive Committee of Bayer CropScience as Head of Research & Development responsible for the integration of the company’s R&D activities into one global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-Wülfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs. From 1988-2007, Dr. Nicholson held various positions of increasing seniority in the UK, the Netherlands and the USA with Organon, a Business Unit of Akzo Nobel. Ultimately, he became Executive Vice President, Research & Development, and member of the Organon Executive Management Committee. He implemented change programs, leading to maximizing effectiveness in research & development, ensuring customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey as Senior Vice President, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was Vice President Licensing and Knowledge Management at Merck in Rahway, New Jersey, reporting to the President of Merck R&D. As an integration team member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009.

How old is C Nicholson?

C Nicholson is 64, he's been the Lead Independent Director of Actinium Pharmaceuticals Inc since 2008. There are 3 older and 6 younger executives at Actinium Pharmaceuticals Inc. The oldest executive at Actinium Pharmaceuticals Inc is Ajit Shetty, 73, who is the Independent Director.

What's C Nicholson's mailing address?

C's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.

Insiders trading at Actinium Pharmaceuticals Inc

Over the last 7 years, insiders at Actinium Pharmaceuticals Inc have traded over $0 worth of Actinium Pharmaceuticals Inc stock and bought 79,730 units worth $38,874 . The most active insiders traders include Anil Kapur, Ajit Shetty oraz Sandesh Seth. On average, Actinium Pharmaceuticals Inc executives and independent directors trade stock every 41 days with the average trade being worth of $22,211. The most recent stock trade was executed by Sandesh Seth on 10 December 2018, trading 10,000 units of ATNM stock currently worth $4,400.

What does Actinium Pharmaceuticals Inc do?

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

Actinium Pharmaceuticals Inc executives and stock owners

Actinium Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Sandesh Seth,
  Chairman of the Board, Chief Executive Officer
• Sandesh C. Seth M.B.A., M.S., MBA,
  Chairman & CEO
• Mark Berger,
  Chief Medical Officer
• Dale Ludwig,
  Chief Scientific Officer
• Steve O'Loughlin,
  Principal Financial and Accounting Officer
• Steven O'Loughlin BS,
  CFO & Corp. Sec.
• C. David Nicholson,
  Lead Independent Director
• Richard Steinhart,
  Independent Director
• Ajit Shetty,
  Independent Director
• Jeffrey Chell,
  Independent Director
• Dr. Bernie Cunningham P.M.P., Ph.D.,
  Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
• Dr. Arun Swaminathan Ph.D.,
  Chief Bus. & Commercial Officer
• Dr. Avinash Desai M.D.,
  Chief Medical Officer
• Dr. Mamata Gokhale,
  VP & Global Head of Regulatory Affairs
• Dr. Robert N. Daly M.S., Ph.D.,
  VP & Head of Clinical Operations
• Dr. Qing Liang,
  VP & Head of Radiation Sciences
• Dr. Bernie Cunningham,
  Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
• Dr. David Gould,
  Sr. VP of Corp. Devel. & Corp. Affairs
• Dr. Paul Diamond Esq., Ph.D.,
  VP of Patent & Legal Counsel
• Nitya G. Ray,
  Executive VP
• Anil Kapur,
  Chief Commercial Officer